What stage does AbbVie invest at?

AbbVie invests at the Seed, Series A, Late Stage stages.

What is AbbVie's typical check size?

AbbVie typically writes checks of $300K – $3M.

Where is AbbVie located?

AbbVie is headquartered in Cambridge, US.

Does AbbVie lead rounds?

AbbVie typically participates in rounds rather than leading them.

AbbVie

Venture capitaloperating company · company profile

Cambridge · Seed–Late Stage · 11 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Very early discovery and preclinical therapeutics company-creation partner tightly integrated with AbbVie R&D, offering founders direct in-house expertise in oncology, immunology, neuroscience and development/commercial infrastructure.

Invests inBiotech Cambridge Canada Europe Netherlands United Kingdom United States

Stage

Seed–Late Stage

Check

$300K – $3M

Cambridge, Massachusetts, US

Leads rounds

Follows

Instruments

Equity

Founded

2009

Tracked investments

Team · 11 people

from public directories

Anthony Melendez· Managing Director· New York, New Yorkin 𝕏

Claire Leurent· Managing Director· Boston, Massachusettsin 𝕏

Claire Leurent pairs drug-development experience at Pfizer and Wyeth with cross-institutional venture investing at Samsung, J&J and the NIH, and—while teaching strategy at Northeastern—creates custom deal structures across stages.

John Gustofson· Managing Director· Massachusettsin

Margarita Chavez· Managing Director· Chicago, Illinois, United Statesin

Margarita Chavez serves as a board member at Aligos Therapeutics and works as a venture investor and advisor in the life sciences sector. Her board experience includes roles as chair and committee member across business development, finance, audit, and research and development functions. She has involvement in early-stage investment and mergers and acquisitions within the biotech industry.

Christina Vorvis· Director· Cambridge, Massachusetts, United Statesin

Christina Vorvis is a Massachusetts‑based corporate VC who invests across oncology, immunology, neuroscience, eye care and aesthetics and pairs a PhD in cancer biology with startup and investment‑banking experience.

Donmienne Leung· Director II, Head of AbbVie Ventures Europe· Oxford, England, United Kingdomin

Donmienne Leung leads a dedicated European venture mandate and, after 20+ years as a drug hunter and PhD medicinal chemist with active publications, provides hands-on scientific guidance to biotech boards.

Doug Faunce· Executive Director· Irvine, California, United Statesin

Doug Faunce, PhD immunologist and Head of Search & Evaluation for Eye Care, brings deep retina, glaucoma, front‑of‑eye expertise and focuses on external innovation and creative partnering from Irvine.

Joachim Vogt· Director· Ludwigshafen Am Rhein, Rhineland-Palatinate, Germanyin

Joachim Vogt, based in Rhine‑Neckar, scouts European therapeutic and tech deals, acts as a front‑door partner at events, and pairs over a decade of business development with hands‑on scientific expertise.

Shawna Frazier· Director· San Francisco, California, United Statesin

Shawna Frazier, a San Francisco–based Director and West Coast lead focused on early-stage biotech, combines a Ph.D. scientific background and startup founder experience bridging big‑pharma strategy with Bay Area startups.

Christian Schubert· Head of AbbVie Ventures· Cambridge, Massachusetts, United Statesin

Christian Schubert is a hybrid operator-investor who shapes corporate venture strategy across US, Europe and Asia‑Pacific, pairing genetics, neurobiology and biochemistry training with large‑pharma experience and active biotech board involvement.

c•••@abbvie.comreveal

Anke Reichardt

Founder mafia

The AbbVie mafia →

8 people who came through AbbVie went on to found or lead other companies.

Evan MurphySenior Software EngineerFounded Zitara +1 Matthew RastovacSoftware Engineering InternFounded Atmos +1 Nick GasbarroGovernment Affairs InternFounded Cognizant Ross LeimbergSenior ManagerFounded Cantai Therapeutics Donmienne LeungDirector II, Head of AbbVie Ventures EuropeFounded ThirtyFiveBio Limited Jim Sullivan, Ph.D.Vice President Global DiscoveryFounded Vanquabio Yuga PatelAutomation Engineering InternFounded Ekpa Chirag JoshiEngineering Co-OpFounded Daisy AI

What they invest in

from 2 of 2 portfolio companies

Biotech ×2Healthtech ×1

HQs:Italy×1United States×1

Investments · 2 tracked

founders shown can be your intro path

Entheraentherapharmaceuticals.com in

Enthera Srl is a privately held pharmaceutical company founded in 2016 and based in Milan, Italy.

BiotechHealthtechMilan, IT

Co-investorsSofinnova Partners Indaco Venture Partners Roche Venture Fund JDRF T1D Fund

Ribon Therapeutics in

BiotechLexington, US

Victoria M. Richon(Executive Officer, Director)

BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)

Co-investorsAvego BioScience Capital OUP (Osage University Partners)Peregrine Ventures Novartis Venture Fund The Column Group

Portfolio news

latest coverage across their companies

InduPro raises $77M, begins first human trial of cancer drug – GeekWire

Ribon Therapeutics · geekwire.com · Aug 14, 2026

Enthera Pharmaceuticals Announces Publication in the Journal of Clinical Investigation Supporting the Clinical Development of Ebrasodebart

Enthera · businesswire.com · May 28, 2025

Frequently asked questions

What stage does AbbVie invest at?: AbbVie invests at the Seed, Series A, Late Stage stages.
What is AbbVie's typical check size?: AbbVie typically writes checks of $300K – $3M.
What sectors does AbbVie focus on?: AbbVie focuses on Biotech.
Where is AbbVie located?: AbbVie is headquartered in Cambridge, US.
Does AbbVie lead rounds?: AbbVie typically participates in rounds rather than leading them.

Co-investors · 6

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

Both backed · 1

Enthera

$540K – $27M

RA Capital

RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.

Hatteras Venture Partners

Hatteras Venture Partners is a venture capital firm focused on early-stage life sciences and healthcare companies, backing therapeutics, diagnostics, and businesses aiming to transform healthcare delivery and innovation.

$500K – $4M

Morpheus Ventures

Morpheus Ventures is a venture capital fund that backs early-stage companies and supports founders through the challenges of scaling toward hyper-growth.

$1M – $10M

Agent Capital

Agent Capital is a healthcare venture capital firm that invests in novel, differentiated therapeutics and treatments addressing unmet patient needs across all stages of development.

M Ventures

M Ventures is the corporate venture arm of Merck KGaA based in Darmstadt, Germany, operating from offices in Amsterdam, the US, and Israel. The firm invests globally across early-stage companies and spin-offs in areas aligned with Merck's core business, taking active roles in portfolio company development.

$10.8M

Firms observed investing alongside AbbVie, from public investor directories. Shared companies are the overlap with AbbVie's recorded portfolio.

Similar investors

8VC

8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.

$100K – $50M

Andreessen Horowitz

Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.

$500K – $50M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Bessemer Venture Partners

Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.